AT-130

Overview

AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus ( HBV ) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC 50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells.

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Liver Cancer | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HBV | Products > Signaling Pathways > DNA/RNA Synthesis

Product Information

• Catalog No.: HY-100028
• CAS No.: 211364-06-6
• Molecular Formula: C22H22BrN3O5
• Molecular Weight: 488.33
• Purity: 98.39%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
• Availability: In-stock

Source

Original product source